SLC5A2 and diabetes mellitus: Trials such as DAPA–CKD and EMPA–Kidney have demonstrated that by lowering the elevated UACR, SGLT2 inhibitors protect CKD patients from worsening renal function and decompensated heart failure, regardless of their diabetes status [20,21].